Introduction

Glucocorticoids are widely used for the treatment of glomerulonephritis, vasculitis, and collagen tissue disorders because of their antiinflammatory and immune altering properties. Although the side effects of glucocorticoids are generally well known, only a few articles have been published about their side effects on the cardiovascular system. Despite the fact that atrial fibrillation (AF), ischemic electrocardiographic changes, bundle branch block with supraventricular tachycardia (SVT), severe bradycardia, and sudden death have been reported as results of intravenous (iv) pulse application of methylprednisolone (MPZ) (2, 6, 7, 8, 10), a short acting glucocorticoid agent, only two case reports about oral MPZ using as a possible cause of cardiac side effects have been found (3, 4).

Therefore, we report a patient with membranoproliferative glomerulonephritis who developed AF after oral MPZ treatment.

Case

A 41 year-old man presented with pretibial edema and general weakness. He didn’t have any other comorbidities (hypertension, cardiac disease, etc.). On examination, his heart rate was 82 beats/min regularly, blood pressure was 150/100 mm Hg. The laboratory values were obtained: blood urea nitrogen 92 mg/dl; creatinine 2.7 mg/dl; potassium 4.7 mEq/L. Urinalysis was included: 10–15 erythrocytes; 4–5 leukocytes; 2+ proteinuria. Renal biopsy was done because of hematuria, proteinuria, and renal dysfunction. The results of the renal biopsy proved that the patient had membranoproliferative glomerulonephritis. After the diagnosis was achieved, treatment was initiated with oral fluocortolone (75 mg/d), which is also a short acting glucocorticoid agent, acetylsalicylic acide (100 mg/d), furosemide (40 mg/d), quinapril (10 mg/d). Six weeks after this treatment, we changed fluocortolone for oral MPZ (48 mg/d) because of the transient lack of it in the markets. On the second day of this therapy, he presented with palpitation and mild chest pain. The findings on the physical examination revealed the following: his blood pressure was 130/80 mmHg and pulse was 110 beats/min and irregular. Physical examination showed no murmurs, rubs, or gallops, but an irregular heartbeat. The remainder of the physical examination was normal. His hemoglobin was 11.9 g/dl and the white blood cell count was 18 000/mm3. The following laboratory findings were included: blood urea nitrogen 80 mg/dl; creatinine 2.4 mg/dl; sodium 131 mEq/L; potassium 5.2 mEq/L; albumin 4.4 g/dl; calcium 9.7 mg/dl; total cholesterol 292 mg/dl; triglyceride 235 mg/dl. Urinalysis findings were 3–5 erythrocytes, 3–5 leukocytes, 1+ proteinuria. AF was defined as a rate of 100–130 beats/min on the electrocardiogram. Creatine phosphokinase (CK) and CK-MB levels were normal. Troponin T was negative. Thyroid hormone levels were normal. A fundoscopic examination showed grade I hypertensive retinopathy. Mild left ventricular hypertrophy was ascertained by bedside echocardiographic examination, but no pericardial fluid was present. At elective echocardiography, left atrial size was 33 mm, interventricular septum thickness 8 mm, and left ventricular posterior wall 9 mm. Tallium sintigraphy was normal. At the clinical follow-up, we did not observed hypertension or electrolyte imbalance.
After metoprolol (1 mg), a beta blocker agent, was given intravenously to the patient, arrhythmia recovered to sinus rhythm and pulse rate was decreased to 94 beats/min. Unfortunately, AF repeated approximately 2 hours later. Metoprolol was applied again until the rhythm was regulated. Afterwards, the beta blocker therapy was continued with oral atenolol (25 mg/d). Three days later, AF occurred again and was treated with metoprolol as above. Oral MPZ treatment was finished because we suspected that AF could be a possible adverse reaction to this drug, and we restarted fluocortolone treatment. Atenolol was gradually discontinued in the following four weeks. No symptomatic AF episode occurred during the following five months. Other treatments were not changed.

Discussion

In our patient, AF occurred on the second day of MPZ treatment and reoccurred on the fifth day of the drug administration. After returning to fluocortolone, AF did not occur over the course of the following five months. We didn’t determine any other pathology contributing to AF out of MPZ treatment. Although he had mild hypertension on his history, he was normotensive during the two episodes of atrial fibrillation. In a report, MPZ was accused of marked bradycardia in a 14-year-old patient with rapidly progressive glomerulonephritis after using both iv and oral form of MPZ, consecutively (4). They suggested that a high dose of oral or iv application of MPZ may cause adverse effect on the cardiovascular system. In addition, Lucas et al. pointed out that the speed of administration could be an important factor for this situation (5). In another article, a patient who had paroxysmal atrial tachycardia attacks that could have been with vagal maneuvers for the last 35 years was reported. Oral MPZ (30 mg) was started for treatment of his acute shoulder pain. During the second day of medication, SVT that didn’t respond to vagal maneuver occurred and then AF followed. AF was recovered after the patient swallowed 20 mg of nadolol and discontinued the methylprednisolone. During the following six years, AF was not observed, inspite of SVT attacks (3). However, it is interesting that pulse MPZ was not applied to our patient and he didn’t have underlying rhythm disorders as described in the above two cases. In addition, we only exchanged fluocortolone for oral MPZ during a therapy program continuing without any problem.

It was postulated that MPZ mediates calcium and potassium flux across cell membranes (1,4). The linkage of corticosteroids and arrhythmia via potassium efflux seems a sufficient explanation for the effects of high dose pulse therapy (6, 7, 8, 10). Although hypokalemia (8), underlying rhythm disorders (3), and severe pain (9) are the predisposing factors thought to cause arrhythmia, none of these circumstances was found in our patient. However, it is not enough to explain the possible mechanism between lower dose oral MPZ administration and AF in our patient because the potassium serum concentrations are within normal limits (4.5–5.2 meq/L). Also, we could not explain why the fibrillation appeared after methylprednisolone administration and not during the previous therapy with fluocortolon.

In conclusion, although the predisposing factors reported previously were not in our patient, MPZ might cause cardiac problems through undefined mechanisms. Physicians should keep in mind that even low dose of oral MPZ could contribute to atrial fibrillation.

References


Accepted January 2008.